Abstract:Hazel M O'Sullivan, 1 Andrew Feber, 2 Sanjay Popat 1– 3 1 Lung Unit, Royal Marsden NHS Foundation Trust, London, UK; 2 The Institute of Cancer Research, London, UK; 3 National Heart and Lung Institute, Imperial College London, London, UK Correspondence: Sanjay Popat, The Lung Unit, The Royal Marsden Hospital, London, SW3 6JJ, United Kingdom, Tel +442073528171, Email Circulating tumor DNA (ctDNA) analysis can identify patients with residual disease before it is clinically or radiologically evident. Minimal residual disease (MRD) is an advancing area in the management of radically treated solid tumors. Which MRD assay is optimum and when it should be used is still not defined. Whilst promising, the clinical utility of this technology to guide patient care is still investigational in non-small cell lung cancer (NSCLC) and has not entered routine care. Once technically and clinically optimized, MRD may be utilized to personalize adjuvant therapy, detect disease relapse earlier and improve cure rates. In this review, we discuss the current status of MRD monitoring in NSCLC by summarizing frequently used MRD assays and their associated evidence in NSCLC. We discuss the potential applications of these technologies and the challenge of demonstrating MRD clinical utility in trials. Keywords: MRD, ctDNA, NSCLC, adjuvant therapy, minimal residual disease, non-small cell lung cancer, circulating tumor DNA Cell-free DNA (cfDNA) refers to fragments of DNA released into the circulation by endothelial cells and white blood cells by active release or passively through apoptosis and necrosis. 1,2 The fraction of cfDNA that originates from tumor is known as circulating tumor DNA (ctDNA). In 2016 the first commercial ctDNA test was approved for use in non-small cell lung cancer (NSCLC); the cobas EGFR mutation test, a real-time polymerase chain reaction (PCR) companion diagnostic test, was designed to identify advanced stage NSCLC patients eligible for treatment with erlotinib. 3 Since then, ctDNA use has exponentially increased in the management of advanced NSCLC. In the advanced setting, evidence supports the use of multigene next generation sequencing (NGS) ctDNA assays upfront, concurrently, or sequentially with tissue biopsies to genotype newly diagnosed patients. ctDNA analysis is also advantageous throughout treatment. In multiple solid tumors, including NSCLC, a "molecular response" has been shown to correlate with superior clinical outcomes. This refers to a reduction in ctDNA variant allele frequency (VAF) following the initiation of treatment and may identify a response to therapy earlier than imaging. 4–13 In oncogene-addicted NSCLC, ctDNA analysis is frequently used at the point of disease progression to potentially identify any resistance mechanisms to aid next-line treatment selection. 14,15 Furthermore, ctDNA VAF is prognostic in early NSCLC, stage I patients with preoperatively detectable ctDNA have an increased risk of recurrence compared to those with stage I disease with no ctDNA identified prior to resection. 16 This suggests the presence of detectable ctDNA in such patients may represent the existence of occult micro metastatic disease at the time of surgery. ctDNA can also be used in the surveillance of radically treated patients to detect minimal residual disease (MRD), i.e., molecular evidence of cancer soon after curative treatment. In contrast to the management of a metastatic patient, where ctDNA assessment is necessary to identify specific targetable alterations to guide therapy, in the radical setting it is the presence of ctDNA in any quantity, not quality, which is important. However, MRD identification is challenging. Assays need to be sufficiently sensitive to detect the small fraction of tumor-derived ctDNA among the abundant cfDNA from normal cells, risking false negative and false positive results. Moreover, even if MRD can be reliably assessed, it's assessment is not currently recommended by international guidelines as the clinical utility is yet to be sufficiently established, randomized trials are ongoing to define this. Once optimized, MRD status may be used to personalize adjuvant therapy, detect disease relapse earlier, and improve cure rates. In this review, we summarize frequently used MRD assays and their associated observational evidence in NSCLC. We discuss the potential applications of these technologies and the challenge of demonstrating MRD clinical utility in trials. Assays used in the detection of MRD can be divided into the tumor genotype informed and genotype uninformed (Figure 1). The tumor informed approach involves prior knowledge of a tumor genotype, via analysis of a tumor specimen and/or preoperative cfDNA, to develop and customize a panel of mutatio -Abstract Truncated-

Abstract A022: Novel technology affords real-time PCR the sensitivity required for minimal residual disease monitoring

Real-time Digital Polymerase Chain Reaction (PCR) As a Novel Technology Improves Limit of Detection for Rare Allele Assays.

Abstract 5037: Development of multiplexed Absolute Q digital PCR assays to rapidly quantify EGFR and KRAS genotype in advanced non-small cell lung cancer (NSCLC) patients' plasma

Abstract 5033: Sub-0.01% KRAS G12C dPCR variant detection by mutation specific blocker (MSB) cassettes

Abstract 3706: Single cell and cell-free nucleic acid analyses of liquid biopsy specimens from a blood collection tube using a new droplet digital PCR system

Abstract P2-01-13: Longitudinal circulating tumor DNA (ctDNA) monitoring by digital droplet PCR (ddPCR) in metastatic breast cancer

Abstract 1959: Sensitive detection of circulating tumor DNA by whole genome sequencing: Validation of MRDetect using serial blood samples from stage III colorectal cancer patients

Abstract PD5-03: PD5-03 Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial

Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

Abstract A035: CRC MRD Detection Using Accu-ActTM NGS Technology

Single-molecule detection of cancer mutations using a novel PCR-LDR-qPCR assay

ddPCR Overcomes the CRISPR-Cas13a-Based Technique for the Detection of the BRAF p.V600E Mutation in Liquid Biopsies

Abstract 6598: the Development of a Tumor-Agnostic Liquid Biopsy Assay for Minimal Residual Disease Detection and Monitoring in Cancers

Abstract 3253: Droplet digital PCR is a sensitive method for detecting refractory acute myeloid leukemia (AML) clones in peripheral blood and saliva

Abstract 2314: Development of a 6-color multiplex Crystal Digital PCR assay for the detection of ESR1 and PIK3CA mutations in the plasma of metastatic breast cancer patients

Abstract A020: Enhanced cell-free RNA (cfRNA) recovery for liquid biopsy applications: Comparative analysis using controlled RNA samples for early and advanced cancer detection

Abstract 2428: Novel ctDNA technology for early cancer detection by immunoprecipitation of tumor associated ctDNA fragments and analysis by qPCR

Abstract CT023: Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study

Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions

Abstract 5581: Clinical validation of a highly sensitive assay to detect mutations in plasma from advanced lung adenocarcinoma patients

Abstract PO3-13-09: Personalized ctDNA testing for detection of molecular residual disease in patients with localized HR+ breast cancer: temporal dynamics and impact on clinical outcomes